21 |
Desenvolvimento de processo cromatográfico para purificação de fator VIII humano. Emprego de anticorpos contra fragmentos específicos da proteína na avaliação da pureza e estabilidade durante as etapas de purificação. / Process development for human factor VIII purification by chromatography, the use of specific antibodies against fragments of the protein for evaluation of purity and stability during purification processes.Jinzenji, Daniela 31 October 2008 (has links)
O fator VIII de coagulação (FVIII), recombinante ou purificado de plasma, é o biofármaco necessário para o tratamento da hemofília A, a doença hemorrágica mais freqüente em humanos. O método tradicional para a purificação de FVIII parte de crioprecipitado de plasma e precipitação alcoólica. No Instituto Butantan, foi proposto um método alternativo, utilizando somente cromatografia para esta purificação. Este projeto teve por objetivo comparar dois métodos cromatográficos de purificação do FVIII: 1 - gel filtração direta do plasma e 2 - pré-purificação de FVIII do plasma por cromatografia de troca aniônica, seguida de gel filtração. A purificação foi analisada por dosagens de atividade específica de FVIII e presença de outras proteínas da cascata de coagulação nas frações de cromatografia. Foram realizadas clonagem de fragmentos gênicos de FVIII e expressão de fragmentos protéicos para imunização de animais. Os soros com anticorpos policlonais anti-FVIII foram usados em ensaios de \"western blot\" para detectar as cadeias de FVIII ou degradação. / Coagulation factor VIII (FVIII), recombinant or purified from plasma, is the biopharmaceutical used for treatment of haemophilia A, the most frequent human hemorrhagic disorder. The traditional method used for purification of FVIII starts from plasma cryoprecipitate and alcoholic precipitation. The Instituto Butantan proposed an alternative methodology using only chromatography for FVIII purification. The main objective of this project was to compare two chromatographic methods for FVIII purification: 1 - direct plasma gel filtration and 2 - pre-purification of FVIII by anion exchange chromatography, followed by gel filtration. The purification process was analyzed by determination of FVIII specific activity and detection of other coagulation factors co eluting in chromatographic fractions. Fragments of FVIII gene were cloned and protein fragments were expressed for animal immunization. Sera with polyclonal antibodies anti-FVIII were used in western blots assays to detect FVIII chains or its degradation.
|
22 |
Kongenitální choroby skotu / Congenital disorders by cattleKOSOBUDOVÁ, Hana January 2012 (has links)
In the framework of this thesis was performed genotyping of 46 specimens of the breed Czech red cattle from the University farm in Czech Budejovice, which monitored the incidence of autosomal recessive genetic disorders, specifically bovine citrullinemia (BC) in exon 5 and deficiency of blood coagulation factor XI (FXI) in exon 9 and 12. Genotyping for BC was done using PCR/RFLP methods and for the disorder FXI in both exons genotypes were determined on the basis of different length of fragments using PCR technology and horizontal agarose electrophoresis. The presence of mutant allele was detected only in the locus for BC and that is in 7 heterozygous carriers, who produced three bands with a length of 185 bp fragments, 103 bp and 82 bp. The frequency of mutant allele and the frequency of heterozygous carriers to 7.6% and 15.2%. Results of the study show that the presence of mutant allele for BC in our tested panel of animals is relatively high. In the future it will be necessary to adopt measures that will lead to the elimination of this allele. Otherwise, its further dissemination would have a negative impact on the health of the population and there might occur complications in the regeneration of Czech red cattle, which is one of our farm animal genetic resources. The literature review deals with the problems of congenital disorders and discusses the importance of health heredity and understanding of the genomic information of cattle.
|
23 |
Isolamento, caracterização bioquímica e funcional in vitro e in vivo de uma metaloprotease isolada da peçonha de Bothrops moojeni envolvida no processo de ativação de fatores da cascata de coagulação / Purification, biochemical and functional characterization in vitro and in vivo of a metalloprotease isolated from Bothrops moojeni snake venom involved in the activation of coagulation factorsMarco Aurélio Sartim 18 August 2014 (has links)
Distúrbios de hemostasia são uma das principais manifestações clínicas observadas nos acidentes por serpentes do gênero Bothrops. Tendo em vista a importância da ativação de fatores da cascata de coagulação no desenvolvimento da patologia no envenenamento, o presente trabalho descreve o isolamento e a caracterização bioquímica e funcional de uma metaloprotease capaz de induzir a ativação de fatores de coagulação, a partir da peçonha de Bothrops moojeni. A metaloprotease foi isolada por três etapas cromatográficas utilizando colunas de exclusão molecular (Sephacryl S-200), interação hidrofóbica (Phenyl Sepharose) e troca aniônica (ES 502N). A protease isolada, denominada moojenactivase, é uma glicoproteína com massa molecular de aproximadamente 89 kDa e ponto isoelétrico de 4,92, sendo composta por três cadeias com massas de 66; 17 e 14 kDa, ligadas por pontes dissulfeto. A determinação da sequência de aminoácidos por espectrometria de massas evidenciou grande identidade sequencial com outras metaloproteases, indicando a presença dos domínios metaloprotease, desintegrina-like e lectinas-like e classificando-a como uma protease da classe PIIId. Funcionalmente, a moojenactivase foi capaz de induzir a cogulação de plasma humano pela ativação dos fatores II (protrombina) e X da cascata de coagulação, gerando -trombina e fator X ativado, respectivamente. A protease apresentou atividade fibrinogenolítica, especialmente sobre a cadeia da molécula de fibrinogênio, porém não foi capaz de induzir a formação do coágulo de fibrina pela ativação deste. A moojenactivase foi parcialmente inibida quando incubada em condições de pH entre 3,5 e 5,0 e em pH 9,0, além de temperaturas acima de 60ºC, bem como na presença de ions Cu2+, além dos inibidores EDTA, SDS, DTT e soro anti-ofídico crotalico/botrópico. A protease induziu agregação plaquetária e não apresentou atividades fibrinolítica e hemorrágica. Células mononucleares de sangue periférico (PBMC) tratadas com a protease foram capazes de produzir TNF- assim como expressar fator tecidual (Fator III da coagulação) na forma ativa, fazendo com que essas células apresentassem caráter procoagulante. Com o objetivo avaliar os efeitos nos parâmetros hematológicos in vivo, a moojenactivase foi administrada em ratos (3g/Kg) onde foi observado que a protease foi capaz de prolongar o tempo de sangramento dos animais e induzir a diminuição do número de plaquetas sanguíneas, caracterizando um quadro de trombocitopenia. Ainda, o plasma dos animais administrados com a moojenactivase apresentaram valores elevados do tempo de protrombina e tempo de tromboplastina parcialmente ativada, assim como redução na concentração de fibrinogênio. Na análise dos parâmetros da série branca, foi observado aumento leucocitário na circulação, com predominância de neutrófilos até 3h após a administração, indicando a instalação de um quadro inflamatório. Com relação à análise da série vermelha, a moojenactivase não foi capaz de alterar nenhum dos parâmetros estudados. Os resultados obtidos no presente trabalho mostram, pela primeira vez, o isolamento de uma metaloprotease da classe P-IIId da peçonha de Bothrops moojeni capaz de atuar sobre diferentes ii eventos do processo hemostático, sendo essa ação prócoagulante responsável pelo quadro de incoagulabilidade sanguínea em animais. Os dados gerados podem auxiliar no entendimento dos distúrbios de coagulação em pacientes envolvidos em acidentes por serpentes da espécie Bothrops moojeni, levando ao melhor direcionamento na terapia anti-ofídica. Ainda, a função da moojenactivase sobre componentes biológicos credencia a molécula para uma possível aplicação biotecnológica em processos que envolvem o sistema hemostático. / Haemostasis disorders are a major clinical manifestation induced by Bothrops snake envenomations. Considering the relevance of the activation of coagulation factors during the envenomation pathophysiology, the present work describes, for the first time, the isolation and functional and biochemical characterization of a coagulation factor activator metalloprotease from Bothrops moojeni snake venom. The protease was purified by three chromatographic procedures using size exclusion (Sephacryl S-200), hydrophobic interaction (Phenyl Sepharose) and anion exchange (ES 502N) chromatographies. The isolated protease, named moojenactivase, is a glycoprotein with molecular mass of approximately 89 kDa by SDS-PAGE, and composed of 66 kDa, 17 kDa and 14 kDa disulfide linked chains, with pI of 4,92. The amino acid sequence determination of tryptic peptides from moojenactivase by mass spectrometry presented fragments with high identity to snake venom metalloproteases, confirming the presence of the metalloprotease, disintegrin-like and lectin-like domains, which allowed its classification as a PIIId class snake venom metalloprotease. Regarding its functional properties, the protease was capable to induce human plasma coagulation by inducing activation of coagulation factors II and X, forming-thrombin and factor X activated, respectively. Also, moojenactivase presented fibrinogenolitic activity, by cleaving preferentially -chain of fibrinogen, however was not capable to induce the formation of fibrin clot from fibrinogen. The enzyme stability was assessed and showed that moojenactivase presented a reduced functional activity when preincubated in pH values ranging from 3,5 to 5,0 and at pH 9,0, and in temperature conditions over 60ºC. Cu2+ ions and inhibitors such as EDTA, SDS, DTT and crotalic/bothropic antiophidian serum reduced the protease activity. Moojenactivase induced platelet aggregation, but no fibrinolytic and haemorrhage activities. In order to evaluate the stimulation of peripheral blood mononuclear cells (PBMC), cells were treated with the protease and we observed the release of proinflammatory cytokine TNF- and expression of active Tissue Factor (coagulant factor III), inducing a procoagulant state on PBMC. In order to evaluate in vivo haematological effects, the protease (3 g/Kg) was administered in rat (i.v.) and was observed that moojenactivase induced a prolonged bleeding time and reduced platelet counting (indicating a thrombocytopenia state). Moreover, the evaluation of the hemostasis parameters was assessed by the the prothrombin time and activated partial thromboplastin time assays and showed a prolonged clot time on both tests, and also a decrease in fibrinogen plasma levels. The leukogram analysis showed an increase in the circulating leukocyte number up to 3 hours after moojenactivase administration, composed predominantly of neutrophils. However, parameters envolving red cells shows that the protease do not affect. The results obtained in the present work show, for the first time, the isolation of a PIIId class metalloprotease from Bothrops moojeni snake venom involved on the activation of several hemostatic events, inducing a pro coagulant activity and leading to blood unclottable state in experimental animals. These data can assit in understanding coagulation disturbs in iv patients involved in Bothrops moojeni envenomation and leading to a better anti ophidic therapy guidance. Moreover, moojenactivase functional activities accredits this protease as a possible molecular instrument applied on biotechnological prospect related to the hemostasis.
|
24 |
Desenvolvimento de processo cromatográfico para purificação de fator VIII humano. Emprego de anticorpos contra fragmentos específicos da proteína na avaliação da pureza e estabilidade durante as etapas de purificação. / Process development for human factor VIII purification by chromatography, the use of specific antibodies against fragments of the protein for evaluation of purity and stability during purification processes.Daniela Jinzenji 31 October 2008 (has links)
O fator VIII de coagulação (FVIII), recombinante ou purificado de plasma, é o biofármaco necessário para o tratamento da hemofília A, a doença hemorrágica mais freqüente em humanos. O método tradicional para a purificação de FVIII parte de crioprecipitado de plasma e precipitação alcoólica. No Instituto Butantan, foi proposto um método alternativo, utilizando somente cromatografia para esta purificação. Este projeto teve por objetivo comparar dois métodos cromatográficos de purificação do FVIII: 1 - gel filtração direta do plasma e 2 - pré-purificação de FVIII do plasma por cromatografia de troca aniônica, seguida de gel filtração. A purificação foi analisada por dosagens de atividade específica de FVIII e presença de outras proteínas da cascata de coagulação nas frações de cromatografia. Foram realizadas clonagem de fragmentos gênicos de FVIII e expressão de fragmentos protéicos para imunização de animais. Os soros com anticorpos policlonais anti-FVIII foram usados em ensaios de \"western blot\" para detectar as cadeias de FVIII ou degradação. / Coagulation factor VIII (FVIII), recombinant or purified from plasma, is the biopharmaceutical used for treatment of haemophilia A, the most frequent human hemorrhagic disorder. The traditional method used for purification of FVIII starts from plasma cryoprecipitate and alcoholic precipitation. The Instituto Butantan proposed an alternative methodology using only chromatography for FVIII purification. The main objective of this project was to compare two chromatographic methods for FVIII purification: 1 - direct plasma gel filtration and 2 - pre-purification of FVIII by anion exchange chromatography, followed by gel filtration. The purification process was analyzed by determination of FVIII specific activity and detection of other coagulation factors co eluting in chromatographic fractions. Fragments of FVIII gene were cloned and protein fragments were expressed for animal immunization. Sera with polyclonal antibodies anti-FVIII were used in western blots assays to detect FVIII chains or its degradation.
|
25 |
DNA methylation of F2RL3 and AHRR and lung cancer riskNguyen, Alice 12 1900 (has links)
Introduction: L'étude des biomarqueurs a le potentiel de documenter sur les mécanismes sous-jacents de l'étiologie du cancer du poumon. Dans cette étude, nous avons étudié l’association entre la méthylation de l’ADN dans les gènes F2RL3 et AHRR et le cancer du poumon.
Méthodes: Une étude cas-témoin avec échantillonnage cumulatif a été nichée dans la cohorte CARTaGENE. Les cas (N=187) se composent de tous les participants diagnostiqués avec un cancer du poumon incident entre le début de la cohorte (2009) et 2015 et qui avaient fourni un échantillon de sang; les témoins (N=378) ont été échantillonnés à la fin du suivi parmi les non-malades selon un appariement fréquentiel (2:1) pour l'âge, le sexe et le moment du prélèvement sanguin. Sequenom EpiTYPER® a été utilisé pour quantifier les niveaux de méthylation dans sept et 33 sites CpG de F2RL3 et AHRR, respectivement. Les rapports de méthylation de l'ADN sur tous les sites CpG individuels et en tant que mesure moyenne ont été paramétrés à la fois comme variables continues et catégorielles. Une régression logistique multivariable non conditionnelle a été utilisée pour estimer les rapports de cotes (OR) et les intervalles de confiance (IC) à 95 % de l’association entre la méthylation de F2RL3 et AHRR et le cancer du poumon tout en contrôlant les facteurs de confusion identifiés à l'aide de graphiques acycliques dirigés.
Résultats: Une forte association inverse entre les niveaux moyens de méthylation de l'ADN et le cancer du poumon a été observée pour F2RL3 (OR par écart type (SD) de changement de méthylation = 0,65, IC à 95 %: 0,53-0,80) et AHRR (OR par SD de changement de méthylation = 0,66, IC à 95 %: 0,53 à 0,80). De même, les sites CpG individuels ont montré des ORs (par SD de changement de méthylation) allant de 0,61 à 0,70 pour six des sept sites CpG de F2RL3 et de 0,57 à 0,79 pour 17 des 33 sites CpG de AHRR. Les sites CpG restants de F2RL3 et AHRR n'ont montré aucune association avec le risque de cancer du poumon, à l'exception d'un site CpG dans AHRR (chr5:369774) qui avait un OR de 1,25 (IC à 95 %: 1,02-1,54).
Conclusion : Ces résultats confirment le rôle des mécanismes épigénétiques dans l'étiologie du cancer du poumon. / Background: The study of biomarkers has the potential to inform on underlying mechanisms in lung cancer etiology. In this study, we investigated DNA methylation in the F2RL3 and AHRR genes, and lung cancer risk.
Methods: A case-control study with cumulative sampling was nested in the CARTaGENE cohort. Cases (N=187) consisted of all participants diagnosed with incident lung cancer from baseline to 2015 and who had provided a blood sample; controls (N=378) were sampled at a ratio of 2:1 with frequency-matching by age, sex, and timing of blood sampling. Sequenom EpiTYPER® was used to quantify methylation levels in seven and 33 CpG sites of F2RL3 and AHRR, respectively. DNA methylation ratios across all individual CpG sites and as an average measure were parametrized both as continuous and categorical variables. Unconditional multivariable logistic regression was used to estimate odds ratios (ORs) and 95% confidence intervals (CI) for lung cancer associated with F2RL3 and AHRR methylation while controlling for confounders identified using directed acyclic graphs.
Results: A strong inverse relationship between average DNA methylation levels and lung cancer was observed for both F2RL3 (OR per standard deviation (s.d.) in methylation change = 0.65, 95% CI: 0.53-0.80) and AHRR (OR per s.d. in methylation change = 0.66, 95% CI: 0.53-0.80). Similarly, ORs for individual CpG sites (per s.d. in methylation change) ranged from 0.61-0.70 for six out of the seven CpG sites of F2RL3 and from 0.57-0.79 for 17 out of 33 CpG sites of AHRR. The methylation levels of the remaining CpG sites within F2RL3 and AHRR were not associated with lung cancer risk, except for one CpG site within AHRR (chr5:369774) which had an OR of 1.25 (95% CI: 1.02-1.54).
Conclusion: These findings support the role of epigenetic mechanisms in lung cancer etiology.
|
26 |
Interplay between 2-oxoglutarate oxygenases and cancer : studies on the aspartyl/asparaginyl-beta-hydroxylasePfeffer, Inga January 2014 (has links)
No description available.
|
Page generated in 0.0935 seconds